NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Status RECRUITING Phase PHASE3
NCT06469138 A Study to Investigate 14C-bemcentinib in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT06424626 A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma Status NOT_YET_RECRUITING Phase PHASE1
NCT06369428 Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients Status COMPLETED Phase N/A
NCT06236360 Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet Status RECRUITING Phase NA
NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Status COMPLETED Phase PHASE2
NCT06075524 Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types Status RECRUITING Phase N/A
NCT06066138 A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Status RECRUITING Phase PHASE1
NCT06060613 Safety and Efficacy of OBX-115 in Advanced Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT05954546 A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings Status COMPLETED Phase N/A
NCT05913388 GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma Status RECRUITING Phase PHASE2
NCT05896839 Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT05856565 Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1 Status RECRUITING Phase N/A
NCT05848219 Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib Status TERMINATED Phase N/A
NCT05810740 Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Status COMPLETED Phase PHASE1